Jak2巨核细胞中p19/CDK4/CDK6轴的失调加速了骨髓纤维化的发展。 - Suppr

Deregulation of the p19/CDK4/CDK6 axis in Jak2 megakaryocytes accelerates the development of myelofibrosis.

作者信息

Duparc Hélène, Muller Delphine, Gilles Laure, Chédeville Agathe L, El Khoury Mira, Guignard Rose, Debili Najet, Wittner Monika, Kauskot Alexandre, Pasquier Florence, Antony-Debré Iléana, Marty Caroline, Vainchenker William, Plo Isabelle, Raslova Hana

机构信息

INSERM, UMR1287, Gustave Roussy, Equipe labellisée Ligue Nationale Contre le Cancer, Villejuif, France.

Université Paris-Saclay, Gif-sur-Yvette, Villejuif, France.

出版信息

Leukemia. 2024 Apr;38(4):898-902. doi: 10.1038/s41375-024-02170-5. Epub 2024 Feb 20.

DOI:10.1038/s41375-024-02170-5

PMID:38378843

Abstract

摘要

相似文献

Deregulation of the p19/CDK4/CDK6 axis in Jak2 megakaryocytes accelerates the development of myelofibrosis.

Leukemia. 2024 Apr;38(4):898-902. doi: 10.1038/s41375-024-02170-5. Epub 2024 Feb 20.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

The Role of Megakaryocytes in Myelofibrosis.

Hematol Oncol Clin North Am. 2021 Apr;35(2):191-203. doi: 10.1016/j.hoc.2020.11.004. Epub 2021 Jan 11.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Mod Pathol. 2007 Sep;20(9):929-35. doi: 10.1038/modpathol.3800826. Epub 2007 Jul 20.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Ann Hematol. 2007 Apr;86(4):245-53. doi: 10.1007/s00277-007-0252-3. Epub 2007 Jan 30.

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.

Ann Lab Med. 2012 Nov;32(6):385-91. doi: 10.3343/alm.2012.32.6.385. Epub 2012 Oct 17.

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

Thromb Res. 2009 Sep;124(4):409-17. doi: 10.1016/j.thromres.2009.02.004. Epub 2009 Mar 18.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7.

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.

Haematologica. 2008 Nov;93(11):1635-44. doi: 10.3324/haematol.13043. Epub 2008 Sep 24.

Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.

Pathobiology. 2007;74(2):72-80. doi: 10.1159/000099120.

引用本文的文献

Gene expression-based rationale for investigating CDK4/6 inhibitors in primitive myelofibrosis.

Leukemia. 2025 Sep;39(9):2299-2301. doi: 10.1038/s41375-025-02669-5. Epub 2025 Jul 1.

Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis.

iScience. 2024 Dec 2;28(1):111522. doi: 10.1016/j.isci.2024.111522. eCollection 2025 Jan 17.

A modern overview of the process of platelet formation (thrombocytopoiesis) and its dependence on several factors.

Biochem Med (Zagreb). 2024 Oct 15;34(3):030503. doi: 10.11613/BM.2024.030503.

本文引用的文献

CDK6 Is a Therapeutic Target in Myelofibrosis.

Cancer Res. 2021 Aug 15;81(16):4332-4345. doi: 10.1158/0008-5472.CAN-21-0590. Epub 2021 Jun 18.

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.

Clin Cancer Res. 2021 Jun 15;27(12):3456-3468. doi: 10.1158/1078-0432.CCR-20-4898. Epub 2021 Mar 29.

EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis.

J Exp Med. 2019 Mar 4;216(3):587-604. doi: 10.1084/jem.20181074. Epub 2019 Feb 7.

CDK6 coordinates mutant MPN via NF-κB and apoptotic networks.

Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Blood. 2012 Aug 9;120(6):1202-9. doi: 10.1182/blood-2012-02-414631. Epub 2012 Jun 20.

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Blood. 2010 Apr 29;115(17):3589-97. doi: 10.1182/blood-2009-04-215848. Epub 2010 Mar 2.

P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1.

Blood. 2008 Apr 15;111(8):4081-91. doi: 10.1182/blood-2007-09-113266. Epub 2008 Feb 14.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

PLoS Med. 2006 Jul;3(7):e270. doi: 10.1371/journal.pmed.0030270.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Deregulation of the p19/CDK4/CDK6 axis in Jak2 megakaryocytes accelerates the development of myelofibrosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献